These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1567483)
1. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Mau BL; Powis G Biochem Pharmacol; 1992 Apr; 43(7):1621-7. PubMed ID: 1567483 [TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Mau BL; Powis G Biochem Pharmacol; 1992 Apr; 43(7):1613-20. PubMed ID: 1567482 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones. Mau BL; Powis G Free Radic Res Commun; 1990; 8(4-6):365-72. PubMed ID: 2162313 [TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Schallreuter KU; Gleason FK; Wood JM Biochim Biophys Acta; 1990 Aug; 1054(1):14-20. PubMed ID: 2200526 [TBL] [Abstract][Full Text] [Related]
5. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187 [TBL] [Abstract][Full Text] [Related]
7. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Engman L; Kandra T; Gallegos A; Williams R; Powis G Anticancer Drug Des; 2000 Oct; 15(5):323-30. PubMed ID: 11354308 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Gallegos A; Berggren M; Gasdaska JR; Powis G Cancer Res; 1997 Nov; 57(21):4965-70. PubMed ID: 9354464 [TBL] [Abstract][Full Text] [Related]
9. Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes. Yu MK; Moos PJ; Cassidy P; Wade M; Fitzpatrick FA J Biol Chem; 2004 Jul; 279(27):28028-35. PubMed ID: 15123685 [TBL] [Abstract][Full Text] [Related]
10. Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat. Moore DJ; Powis G; Richardson RL; Pittelkow MR Cancer Res; 1985 Nov; 45(11 Pt 1):5466-72. PubMed ID: 4053022 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives. Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422 [TBL] [Abstract][Full Text] [Related]
13. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Oblong JE; Chantler EL; Gallegos A; Kirkpatrick DL; Chen T; Marshall N; Powis G Cancer Chemother Pharmacol; 1994; 34(5):434-8. PubMed ID: 8070012 [TBL] [Abstract][Full Text] [Related]
14. Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity. Cory JG; Cory AH; Raber NK; Narayanan A; Schneller SW Adv Enzyme Regul; 1993; 33():129-40. PubMed ID: 8356905 [TBL] [Abstract][Full Text] [Related]
15. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Smart DK; Ortiz KL; Mattson D; Bradbury CM; Bisht KS; Sieck LK; Brechbiel MW; Gius D Cancer Res; 2004 Sep; 64(18):6716-24. PubMed ID: 15374989 [TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Tisdale MJ; Habberfield AD Biochem Pharmacol; 1980 Oct; 29(20):2845-53. PubMed ID: 7002161 [No Abstract] [Full Text] [Related]
17. Photosensitization of MCF-7 cells with diaziquone using visible light: correlation with DNA strand breaks and free radical production. al-Nabulsi I; Gutierrez PL Photochem Photobiol; 1992 Aug; 56(2):201-9. PubMed ID: 1502264 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Chiu CS; Chan AK; Wright JA Biochem Cell Biol; 1992 Dec; 70(12):1332-8. PubMed ID: 1299271 [TBL] [Abstract][Full Text] [Related]
19. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity. Ng HL; Chen S; Chew EH; Chui WK Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844 [TBL] [Abstract][Full Text] [Related]
20. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Lin S; Del Razo LM; Styblo M; Wang C; Cullen WR; Thomas DJ Chem Res Toxicol; 2001 Mar; 14(3):305-11. PubMed ID: 11258980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]